HOME > TOP STORIES
TOP STORIES
-
BUSINESS Shift to Specialty - 4: Ceolia Pharma Aims to Be Single-Source Provider in Field of ENT
October 28, 2015
-
REGULATORY 6 Drugs Get Sakigake Designation for Fast-Track Review
October 27, 2015
-
BUSINESS Jardiance Cardiovascular Data Boon for Japan’s Floundering SGLT-2 Inhibitor Space?
October 26, 2015
-
REGULATORY MHLW Asks Chuikyo to Revise Evaluation for Antipsychotic Therapies in Large Dosages without Adequate Guidance
October 26, 2015
-
BUSINESS Sandoz Looking to Emerge as Top Foreign Generic Maker in Japan in 5 Years
October 23, 2015
-
BUSINESS Shift to Specialty – 3: Meiji Seika Pharma to Focus Pipeline, Optimize Sales Force
October 23, 2015
-
REGULATORY New MHLW Economic Affairs Chief Visits Logistics Center, Says Distribution Key to Brightening Pharma Sector
October 22, 2015
-
BUSINESS Development of Osteoporosis Drugs in Homestretch, Odanacatib’s US Filing Expected by Year-End
October 21, 2015
-
BUSINESS Shift to Specialty – 2: Santen Invests in the Future Over Present Profits
October 21, 2015
-
REGULATORY Patent Extension, Patent Linkage Rules in TPP Require No Rule Changes in Japan: MHLW Official
October 20, 2015
-
BUSINESS Shift to Specialty - 1: Drug Makers Urged to Retool Strategies amid Govt Pressure, Dismal Biz Environment
October 19, 2015
-
BUSINESS Eisai, Ajinomoto Link Arms to Create Leading Specialty Pharma for GI Disease
October 16, 2015
-
REGULATORY Chuikyo Tilting Toward Introduction of Re-Pricing for “Huge Seller” Drugs
October 15, 2015
-
ORGANIZATION AMDJ to Draw Up Voluntary Rules for Managing Big Data in Field of Healthcare
October 14, 2015
-
REGULATORY MOF Pitches Reimbursement Rate Cuts for OTC-Switched Ethical Drugs, Submission of Related Bills Eyed in 2017
October 13, 2015
-
REGULATORY TPP Will Have No Impact on Japan’s Universal Care Scheme: Negotiator
October 9, 2015
-
REGULATORY Chuikyo Payer and Doctor Reps Exchange Barbs on Spike in Generic Brand-Specified Scripts
October 8, 2015
-
REGULATORY 8 Year Biologic Data Protection in TPP Won’t Affect Japan: MHLW Official
October 7, 2015
-
REGULATORY MHLW Looks to Establish Panel to Draft Guidelines for English-Language Inserts
October 6, 2015
-
BUSINESS Belsomra Most Heavily Pitched Drug in July: Anterio Ranking
October 5, 2015
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…